178 related articles for article (PubMed ID: 26501112)
1. Discovery of Genetic Variants of the Kinases That Activate Tenofovir in a Compartment-specific Manner.
Lade JM; To EE; Hendrix CW; Bumpus NN
EBioMedicine; 2015 Sep; 2(9):1145-52. PubMed ID: 26501112
[TBL] [Abstract][Full Text] [Related]
2. Discovery of genetic variants of the kinases that activate tenofovir among individuals in the United States, Thailand, and South Africa: HPTN067.
Figueroa DB; Tillotson J; Li M; Piwowar-Manning E; Hendrix CW; Holtz TH; Bokoch K; Bekker LG; van Griensven F; Mannheimer S; Hughes JP; Grant RM; Bumpus NN
PLoS One; 2018; 13(4):e0195764. PubMed ID: 29641561
[TBL] [Abstract][Full Text] [Related]
3. Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells.
Figueroa DB; Madeen EP; Tillotson J; Richardson P; Cottle L; McCauley M; Landovitz RJ; Andrade A; Hendrix CW; Mayer KH; Wilkin T; Gulick RM; Bumpus NN
AIDS Res Hum Retroviruses; 2018 May; 34(5):421-429. PubMed ID: 29455571
[TBL] [Abstract][Full Text] [Related]
4. Naturally Occurring Mutations to Muscle-Type Creatine Kinase Impact Its Canonical and Pharmacological Activities in a Substrate-Dependent Manner In Vitro.
Mosher EP; Eberhard CD; Bumpus NN
Mol Pharmacol; 2021 Dec; 100(6):588-596. PubMed ID: 34561299
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.
Mallayasamy S; Chaturvedula A; Fossler MJ; Sale M; Goti V; Bumpus NN; Marzinke MA; Hendrix CW; Haberer JE;
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182536
[TBL] [Abstract][Full Text] [Related]
6. A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study).
Mcgowan I; Cranston RD; Duffill K; Siegel A; Engstrom JC; Nikiforov A; Jacobson C; Rehman KK; Elliott J; Khanukhova E; Abebe K; Mauck C; Spiegel HM; Dezzutti CS; Rohan LC; Marzinke MA; Hiruy H; Hendrix CW; Richardson-Harman N; Anton PA
PLoS One; 2015; 10(5):e0125363. PubMed ID: 25942472
[TBL] [Abstract][Full Text] [Related]
7. MALDI Mass Spectrometry Imaging Reveals Heterogeneous Distribution of Tenofovir and Tenofovir Diphosphate in Colorectal Tissue of Subjects Receiving a Tenofovir-Containing Enema.
Seneviratne HK; Hendrix CW; Fuchs EJ; Bumpus NN
J Pharmacol Exp Ther; 2018 Oct; 367(1):40-48. PubMed ID: 30037813
[TBL] [Abstract][Full Text] [Related]
8. Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexposure Prophylaxis.
Nicol MR; Eneh P; Nakalega R; Kaiser T; Kabwigu S; Isingel E; Beksinska M; Sykes C; Fowler MG; Brown TT; Staley C; Kiweewa Matovu F
Clin Infect Dis; 2020 Apr; 70(8):1717-1724. PubMed ID: 31131846
[TBL] [Abstract][Full Text] [Related]
9. The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.
Daly MB; Sterling M; Holder A; Dinh C; Nishiura K; Khalil G; García-Lerma JG; Dobard C
Antiviral Res; 2021 Feb; 186():105001. PubMed ID: 33385420
[TBL] [Abstract][Full Text] [Related]
10. FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir.
Bunge KE; Dezzutti CS; Hendrix CW; Marzinke MA; Spiegel HML; Moncla BJ; Schwartz JL; Meyn LA; Richardson-Harman N; Rohan LC; Hillier SL
J Int AIDS Soc; 2018 Aug; 21(8):e25156. PubMed ID: 30101439
[TBL] [Abstract][Full Text] [Related]
11. Expression, Activity, and Regulation of Phosphorylating Enzymes in Tissues and Cells Relevant to HIV-1 Sexual Transmission.
Hu M; Valicherla GR; Zhou T; Hillier SL; Rohan LC
AIDS Res Hum Retroviruses; 2022 Jan; 38(1):22-32. PubMed ID: 33567990
[TBL] [Abstract][Full Text] [Related]
12. Nucleoside Triphosphate Diphosphohydrolase 1 Exhibits Enzymatic Activity toward Tenofovir Diphosphate.
Seneviratne HK
Drug Metab Dispos; 2023 Mar; 51(3):385-391. PubMed ID: 36396461
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.
Justman JE; Nair GL; Hendrix CW; Piper JM; Marzinke MA; Dai JY; Pan Z; Galaska B; Levy L; Schwartz JL; Balar B; Kunjara Na Ayudhya RP; Mushamiri I; McGowan I; Dezzutti CS;
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):175-182. PubMed ID: 29767639
[TBL] [Abstract][Full Text] [Related]
14. Mutations in muscle-type creatine kinase impact HIV prevention.
Migliorati JM; Zhong XB
Trends Pharmacol Sci; 2022 Mar; 43(3):165-167. PubMed ID: 34887127
[TBL] [Abstract][Full Text] [Related]
15. Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.
Taneva E; Crooker K; Park SH; Su JT; Ott A; Cheshenko N; Szleifer I; Kiser PF; Frank B; Mesquita PM; Herold BC
Antimicrob Agents Chemother; 2015 Dec; 60(3):1667-75. PubMed ID: 26711762
[TBL] [Abstract][Full Text] [Related]
16. The Vaginal Microbiome and its Potential to Impact Efficacy of HIV Pre-exposure Prophylaxis for Women.
Velloza J; Heffron R
Curr HIV/AIDS Rep; 2017 Oct; 14(5):153-160. PubMed ID: 28812207
[TBL] [Abstract][Full Text] [Related]
17. Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using a 90-Day Tenofovir/Levonorgestrel Vaginal Ring.
Thurman AR; Ravel J; Gajer P; Marzinke MA; Ouattara LA; Jacot T; Peet MM; Clark MR; Doncel GF
Front Cell Infect Microbiol; 2022; 12():799501. PubMed ID: 35350436
[TBL] [Abstract][Full Text] [Related]
18. Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.
Hoang T; Date AA; Ortiz JO; Young TW; Bensouda S; Xiao P; Marzinke M; Rohan L; Fuchs EJ; Hendrix C; Gumber S; Villinger F; Cone RA; Hanes J; Ensign LM
Eur J Pharm Biopharm; 2019 May; 138():23-29. PubMed ID: 29802984
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 randomized pharmacokinetic and safety study of a 90-day tenofovir vaginal ring in the United States.
Liu AY; Gundacker H; Richardson B; Chen BA; Hoesley C; van der Straten A; Brown A; Beamer M; Robinson J; Jacobson CE; Scheckter R; Bunge K; Schwartz J; Thurman A; Piper JM; Marzinke MA;
J Int AIDS Soc; 2024 Mar; 27(3):e26223. PubMed ID: 38444118
[TBL] [Abstract][Full Text] [Related]
20. Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel.
Herold BC; Chen BA; Salata RA; Marzinke MA; Kelly CW; Dezzutti CS; McGowan I; Galaska B; Levy L; Piper JM; Hillier S; Hendrix CW
Clin Infect Dis; 2016 Feb; 62(3):375-382. PubMed ID: 26508513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
